Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 8, 2024
Reporting Period: Event-based report regarding a corporate action effective October 16, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-15 reverse stock split of common stock.
- Share Count Reduction: Outstanding shares will decrease from approximately 35.5 million to approximately 2.4 million.
- Effective Date: The split becomes effective on October 16, 2024, at 12:01 a.m. Eastern Time.
- Trading Details: Trading will resume on the Nasdaq Capital Market on October 16, 2024, under the symbol "MGRX" with a new CUSIP number (56270V205).
- Equity Adjustments: Stock options, warrants, and other equity awards have been proportionately adjusted (quantity reduced, exercise price increased) to maintain aggregate value.
- Fractional Shares: No cash will be paid for fractional shares; they will be rounded up to the nearest whole share.
Outlook, Risks, and Management Commentary
Reason for Action: The reverse stock split is intended to satisfy the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement of $1.00 per share. The Company received a deficiency notice on October 30, 2023, and was granted a compliance period extended to October 28, 2024.
Management Commentary: Management expects the split to increase the closing bid price above the $1.00 threshold, thereby avoiding delisting. The split does not alter the par value, voting rights, or percentage ownership of stockholders (excluding minor rounding effects).
Risks and Contingencies: The filing notes that if the Company fails to regain compliance with the bid price requirement by the Compliance Date, it risks delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the new CUSIP number (56270V205) for post-split trading on October 16, 2024.
- Confirm the adjusted number of shares held and the new exercise prices for any outstanding options or warrants.
- Monitor the stock price on October 16, 2024, to determine if the $1.00 minimum bid price requirement is met.
- Review the definitive proxy statement filed on March 1, 2024, for full details on the stockholder authority granted.